Farmas USA

Hoy tenemos resulatdos de HZNP en pre y de NVAX en after; y mañana, CASC en pre y ACAD en after. Yo las llevo las cuatro... a ver cómo sale la cosa.

ACAD CASC HZNP NVAX

Y de entre las grandes, mañana martes tocan Allergan y Valeant; el miércoles, Mylan; y el jueves, Teva.

SGYP +9.5% en premarket por datos positivos en nuevos ensayos clinicos fase III de Trulance

http://www.loncarblog.com/may-8-healthcare-earnings

Ahí tienes todos los ER para esta semana. Una cantidad importante... Más las que no lo anuncian, como DVAX que no son pocas...

RGLS

Nuevo inversor Biotechnology value fund, con 1,5 M de acciones

HZNP

Para calentar motores antes de los ER 

Horizon Pharma plc Announces Agreement to Acquire River Vision Development Corp. and Teprotumumab (RV001), a Biologic in Late-Stage Development for Rare Eye Disease

-     Pivotal Trial of Teprotumumab in Thyroid Eye Disease (TED) Expected to Begin in Second Half of 2017     -

-     Teprotumumab Phase 2 Trial Results Recently Published in The New England Journal of Medicine    -

http://ir.horizon-pharma.com/releasedetail.cfm?ReleaseID=1025196

Horizon Pharma plc Announces Agreement to Acquire River Vision Development Corp. and Teprotumumab (RV001), a Biologic in Late-Stage Development for Rare Eye Disease

- Pivotal Trial of Teprotumumab in Thyroid Eye Disease (TED) Expected to Begin in Second Half of 2017 -

HZNP

Y ya lo tenemos todo

Horizon Pharma plc Announces First-Quarter 2017 Results and Revises Full-Year 2017 Net Sales and Adjusted EBITDA Guidance

-- First-Quarter 2017 Net Sales of $220.9 Million; Up 8 Percent --

-- First-Quarter 2017 Net Loss of $90.6 Million; Adjusted EBITDA of $51.9 Million --

-- First-Quarter 2017 Net Sales from Rare Disease Medicines Increased 75 Percent and  Represented 65 Percent of Total Company Net Sales --

-- Increased Investment in its Rapidly Growing Orphan Biologic Medicine for Refractory Chronic Gout, KRYSTEXXA® --

-- Raising KRYSTEXXA Peak Annual Net Sales Estimate to More than $400 Million from
More than $250 Million --

-- Announces Acquisition of River Vision Development Corp. and Teprotumumab, a Biologic in Late-Stage Development for a Rare Eye Disease --

-- Revising Full-Year 2017 Net Sales Guidance Range to $1.000 Billion to $1.035 Billion and Full-Year 2017 Adjusted EBITDA Guidance Range to $315 Million to $350 Million; Reflects Revisions to the Primary Care Business Unit Assumptions, Increased Investment in KRYSTEXXA and R&D Investment in Teprotumumab --

-- Announces Board of Directors' Authorization of Share Repurchase Program for Approximately
10 Percent of Shares Outstanding --

http://ir.horizon-pharma.com/releasedetail.cfm?ReleaseID=1025208